32 BWA | JUL 2026 in Australia, and became increasingly convinced that the world’s healthcare problems could not be solved by clinicians alone. The same profile says his brother Dimitry brought the business and execution lens to the company’s formation, giving Harrison.ai a founding structure that combined clinical credibility with commercial ambition from the beginning. That pairing still feels central to the way the business presents itself today. That origin story matters because Harrison.ai never really looked like a conventional enterprise-software startup. The company has consistently framed its mission less around “AI transformation” in the abstract and more around the specific pressures facing modern healthcare systems: clinician shortages, rising imaging volumes, delayed diagnosis and growing workflow complexity. Its public materials say the goal is to expand clinician capacity, improve operational efficiency and support earlier disease detection, which is a more grounded and useful framing than many AI-healthcare companies manage. The company’s capital journey also shows how that thesis has matured. In February 2025, Harrison.ai announced a US$112 million Series C, saying the round would support accelerated expansion into the United States and broader scaling of its AI-powered diagnostic and workflow products. Its About page now says total capital raised exceeds US$240 million, which places it among the more heavily backed private AI companies
RkJQdWJsaXNoZXIy MTE4MTQ=